Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal
obstruction more effectively than desloratadine.
Author(s): Dumitru AF, Shamji M, Wagenmann M, Hindersin S, Scheckenbach K, Greve J, Klenzner
T, Hess L, Nebel S, Zimmermann C, Zahner C, Schmidt-Weber CB, Chaker AM.
Affiliation(s): Molecular Immunology, Section of Allergy and Clinical Immunology, National Heart
and Lung Institute, Imperial College London, London, United Kingdom.
Publication date & source: 2011, J Allergy Clin Immunol. , 127(6):1515-21
BACKGROUND: Allergic rhinitis symptoms of itching, sneezing, rhinorrhea, and
nasal obstruction significantly decrease patients' quality of life. Compared with
histamine and leukotriene receptor antagonists, the petasol butenoate complex Ze
339 displays pharmacologically distinct properties. In vitro it inhibits the
biosynthesis of leukotrienes and mediator release from activated eosinophils.
OBJECTIVE: This study aimed to assess the efficacy and mode of action of Ze 339,
desloratadine, and placebo on allergic rhinitis symptoms, nasal airflow, and
local mediator levels after unilateral nasal allergen provocation.
METHODS: In this double-blind, randomized, crossover study 18 subjects with
allergic rhinitis to grass pollen received Ze 339, desloratadine, and placebo for
5 days before nasal allergen challenge with grass pollen extract. Rhinomanometry,
symptom assessment, and local inflammatory mediator measurement were performed
during the 24 hours after allergen challenge.
RESULTS: With Ze 339, the patient's time to recovery (5.4 ± 1.6 hours) from nasal
obstruction after allergen challenge (time for return to 90% of baseline value ±
SEM) was significantly shorter than with placebo (9.1 ± 2.3 hours, P = .035) and
desloratadine (10.7 ± 2.5 hours, P = .022). Likewise, Ze 339's standardized
symptom assessment for nasal obstruction (3.2 ± 1.3 hours) showed significantly
faster relief (time for return to baseline value ± SEM compared with placebo, 8.3
± 2.4 hours; P = .027) and desloratadine (4.5 ± 1.2 hours, P = .030). One
interesting finding was that Ze 339 significantly reduced IL-8 and leukotriene
B(4) levels in nasal secretions before challenge.
CONCLUSION: When compared with desloratadine and placebo, Ze 339 shows better
efficacy in relieving nasal obstruction symptoms and inhibiting critical
components of the chemokine network and as such represents a novel symptomatic
and possible prophylactic treatment for allergic rhinitis.
|